## **Amendments to the Claims**

Claims 1-14 (Cancelled)

Claim 15. (Currently Amended) A compound selected from the group consisting of: 6-{4-[(3-Methyl-butylamino)-methyl]-phenoxy}-nicotinimidic acid ethyl ester

N-Hydroxy-6-{4-[(3-methyl-butylamino)-methyl]-phenoxy}-nicotinamidine

6-{4-[(3-Methyl-butylamino)-methyl]-phenoxy}-nicotinamidine

{4-[5-(4,5-Dihydro-1H-imidazol-2-yl)-pyridin-2-yloxy]-benzyl}-(3-methyl-butyl)-amine

{4-[5-(4,5-Dihydro-1H-imidazol-2-yl)-pyridin-2-yloxy]-benzyl}-(2-thiophen-2yl-ethyl)amine

 $(3-Methyl-butyl) - \\ \{4-[5-(4,5,6,7-tetrahydro-1H-[1,3]diazepin-2-yl)-pyridin-2-yloxy]-benzyl\} - \\ amine$ 

 $(3-Methyl-butyl)-\{4-[5-(1,4,5,6-tetrahydropyrimidin-2-yl[[2-yl]])-pyridin-2-yloxy]-benzyl\}-amine$ 

N-Cyano-6-{4-[(3-methyl-butylamino)-methyl]-phenoxy}-nicotinamidine

 $(3-Methyl-butyl)-\{4-[5-(2H-tetrazol-5-yl)-pyridin-2-yloxy]-benzyl\}-amine$ 

{4-[5-(1H-Imidazol-2-yl)-pyridin-2-yloxy]-benzyl}-(3-methyl-butyl)-amine

 $\textit{N-}(2,2-Dimethoxy-ethyl)-6-\{4-[(3-methyl-butylamino)-methyl]-phenoxy\}-nicotinamidine}$ 

6-{4-[3-Methyl-butylamino)-methyl]-phenoxy}-benzoisoxazol-3-ylamine

6-{4-[(3,3-Dimethyl-butylamino)-methyl]-phenoxy}-benzo[d]isoxazol-3-ylamine

6-(4-{[2-(4-Fluoro-phenyl)-ethylamino]-methyl}-phenoxy)-benzo[d]isoxazol-3-ylamine

6-(4-{[2-(Tetrahydro-pyran-4-yl)-ethylamino]-methyl}-phenoxy)-benzo[d]isoxazol-3-ylamine

6-{4-[(3-Methyl-butylamino)-methyl]-phenoxy}-1H-indazol-3-ylamine

or a pharmaceutically acceptable salt thereof.

Claim 16. (Cancelled)

Claim 17. (Cancelled)

Claim 18. (Previously Presented) A pharmaceutical composition comprising a compound according to Claim 15 in association with a carrier, diluent and/or excipient.

Claim 19. (Cancelled)

Claim 20. (Cancelled)

## Serial No. 10/581,178

Claim 21.	(Cancelled)
Claim 22.	(Cancelled)
Claim 23.	(Cancelled)
Claim 24.	(Cancelled)
Claim 25.	(Cancelled)